Liana F. Van der Gang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liana F. Van der Gang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Celeste M. Boesjes
National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht Utrecht The Netherlands
7 shared publications Marlies de Graaf
7 shared publicationsMarjolein S. de Bruin‐Weller
National Expertise Centre for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Centre Utrecht Utrecht the Netherlands
6 shared publicationsFrancine C. van Erp
5 shared publicationsInge M. Haeck
5 shared publicationsNicolaas P. A. Zuithoff
Julius Centre for Health Sciences and Primary Care University Medical Centre Utrecht Utrecht the Netherlands
5 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , 1505-1508
Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry
- 18 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , 1505-1508
Open AccessDupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry
- Open Access
- 25 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 722-723
Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
- 25 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 722-723
Open AccessTranslating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
- Open Access
- 13 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1359-1371
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay
Background: Dupilumab and tralokinumab for atopic dermatitis (AD) target the type 2 axis through different mechanisms of action, which may lead to variation in effectiveness and safety. Head‐to‐head trials, however, are lacking. Objectives: To compare the real‐world effectiveness and safety of dupilumab and tralokinumab in AD. Methods: This prospective cohort study enrolled biologic−/Janus kinase inhibitor‐naïve AD patients (≥12 years) from the BioDay registry who initiated dupilumab or tralokinumab between November 2021 and September 2024. Visits were scheduled at baseline, 4 weeks and every 3 months up to 52 weeks. Effectiveness outcomes included Eczema Area and Severity Index (EASI), weekly mean pruritus Numeric Rating Scale (NRS), treat‐to‐target thresholds (EASI ≤ 7; NRS‐pruritus ≤ 4, with patients discontinuing treatment considered non‐responders) and drug survival. Adverse events (AEs) were assessed at each visit. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups. Results: In total, 750 patients were included (643 dupilumab; 107 tralokinumab). After IPTW, baseline characteristics were well balanced. During follow‐up, dupilumab patients had lower EASI scores than tralokinumab patients, although differences were not consistently statistically significant ( p = 0.10). NRS‐pruritus scores were significantly lower with dupilumab at all visits ( p < 0.0001), mean differences did not exceed the 2‐point clinical relevance threshold. The probability of achieving EASI ≤ 7 and NRS‐pruritus ≤ 4 was higher with dupilumab (both p < 0.0001), with risk differences of 34.7% and 40.2% at 52 weeks, respectively. After 52 weeks, dupilumab drug survival was 92.6% vs. 70.6% for tralokinumab. Ocular surface disease incidence was similar (HR 1.0, 95% CI 0.6–1.6, p = 0.94) between treatments, leading to discontinuation of dupilumab in n = 23 (3.4/100 PY) and tralokinumab in n = 5 (5.4/100 PY). Conclusions: In this real‐world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS‐pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4, and discontinuation rates were taken into account.
- 13 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1359-1371
Open AccessDupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay
Background: Dupilumab and tralokinumab for atopic dermatitis (AD) target the type 2 axis through different mechanisms of action, which may lead to variation in effectiveness and safety. Head‐to‐head trials, however, are lacking. Objectives: To compare the real‐world effectiveness and safety of dupilumab and tralokinumab in AD. Methods: This prospective cohort study enrolled biologic−/Janus kinase inhibitor‐naïve AD patients (≥12 years) from the BioDay registry who initiated dupilumab or tralokinumab between November 2021 and September 2024. Visits were scheduled at baseline, 4 weeks and every 3 months up to 52 weeks. Effectiveness outcomes included Eczema Area and Severity Index (EASI), weekly mean pruritus Numeric Rating Scale (NRS), treat‐to‐target thresholds (EASI ≤ 7; NRS‐pruritus ≤ 4, with patients discontinuing treatment considered non‐responders) and drug survival. Adverse events (AEs) were assessed at each visit. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups. Results: In total, 750 patients were included (643 dupilumab; 107 tralokinumab). After IPTW, baseline characteristics were well balanced. During follow‐up, dupilumab patients had lower EASI scores than tralokinumab patients, although differences were not consistently statistically significant ( p = 0.10). NRS‐pruritus scores were significantly lower with dupilumab at all visits ( p < 0.0001), mean differences did not exceed the 2‐point clinical relevance threshold. The probability of achieving EASI ≤ 7 and NRS‐pruritus ≤ 4 was higher with dupilumab (both p < 0.0001), with risk differences of 34.7% and 40.2% at 52 weeks, respectively. After 52 weeks, dupilumab drug survival was 92.6% vs. 70.6% for tralokinumab. Ocular surface disease incidence was similar (HR 1.0, 95% CI 0.6–1.6, p = 0.94) between treatments, leading to discontinuation of dupilumab in n = 23 (3.4/100 PY) and tralokinumab in n = 5 (5.4/100 PY). Conclusions: In this real‐world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS‐pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4, and discontinuation rates were taken into account.
- 31 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8)
Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
- 31 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8)
Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
- Open Access
Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry
- Open Access
- 24 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (12) , 2026-2027
Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
- 24 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (12) , 2026-2027
Open AccessReassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
- 2 November 2025
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (11) , 1171-1192
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder and has a considerable impact on patients' quality of life. Dupilumab, the first biologic approved for moderate-to-severe AD, is a human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking both IL-4 and IL-13 signaling, key drivers of type 2 inflammation in AD. Its introduction has marked a paradigm shift in the management of AD and paved the way for future therapies. As real-world evidence on biologics and Janus kinase (JAK) inhibitors is rapidly emerging, comprehensive and up-to-date reviews are important. This review primarily summarizes real-world data on dupilumab, with a focus on its effectiveness and safety in clinical practice, highlighting recent findings and their implications for optimizing patient management. Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.
- 2 November 2025
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (11) , 1171-1192
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder and has a considerable impact on patients' quality of life. Dupilumab, the first biologic approved for moderate-to-severe AD, is a human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking both IL-4 and IL-13 signaling, key drivers of type 2 inflammation in AD. Its introduction has marked a paradigm shift in the management of AD and paved the way for future therapies. As real-world evidence on biologics and Janus kinase (JAK) inhibitors is rapidly emerging, comprehensive and up-to-date reviews are important. This review primarily summarizes real-world data on dupilumab, with a focus on its effectiveness and safety in clinical practice, highlighting recent findings and their implications for optimizing patient management. Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.
- Top Cited PapersOpen Access
- 3 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (12) , 2056-2068
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
Background: Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice. Objectives: To assess the differential infection risk of biologic and JAKi treatment in patients with moderate‐to‐severe AD in a real‐world setting. Methods: This prospective, multicentre study evaluated treatment‐emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient‐years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio‐/JAKi‐naïve patients. Results: In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4–65.5/100 PY) compared to biologics (13.6–22.0), especially for herpes infections ( n = 195, 24.6%; JAKi 13.6–19.8 vs. biologicals 3.0–3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1–5.5; baricitinib HR 4.2, 95% CI: 2.9–6.2; upadacitinib HR 4.0, 95% CI: 3.2–5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0–2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4–2.6, p < 0.0001; 2.4, 1.3–4.4, p = 0.003, resp.), was identified as an independent factor associated with infection. Conclusions: This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate‐to‐severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient‐specific risks such as prior skin infections.
- 3 April 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (12) , 2056-2068
Top Cited PapersOpen AccessInfection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
Background: Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice. Objectives: To assess the differential infection risk of biologic and JAKi treatment in patients with moderate‐to‐severe AD in a real‐world setting. Methods: This prospective, multicentre study evaluated treatment‐emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient‐years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio‐/JAKi‐naïve patients. Results: In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4–65.5/100 PY) compared to biologics (13.6–22.0), especially for herpes infections ( n = 195, 24.6%; JAKi 13.6–19.8 vs. biologicals 3.0–3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1–5.5; baricitinib HR 4.2, 95% CI: 2.9–6.2; upadacitinib HR 4.0, 95% CI: 3.2–5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0–2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4–2.6, p < 0.0001; 2.4, 1.3–4.4, p = 0.003, resp.), was identified as an independent factor associated with infection. Conclusions: This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate‐to‐severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient‐specific risks such as prior skin infections.
- Open Access
- 4 February 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (3) , 260-263
Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment
- 4 February 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (3) , 260-263
Open AccessIncreased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment